A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2004
11/10/2004	CN1543939A Ferulaic acid sodium transfusion and prescription and preparation thereof
11/10/2004	CN1543937A Metformin hydrochloride sustained-release tablet and method for preparing the same
11/10/2004	CN1543936A Sibutramine hydrochloride guttate pill
11/10/2004	CN1175106C Human insulin recombinant gene, preparation method and application
11/10/2004	CN1174972C Method for production of L-ascorbic acid by lactonization of 2-keto-L-gulonic acid or 2-keto-L-gulonate esters
11/10/2004	CN1174926C Production process of organic-state mineral water
11/10/2004	CN1174758C Medicine for treating diabetes and its preparing process
11/10/2004	CN1174744C Thermal formed solid releasing-controlled medicinal composition
11/09/2004	US6815534 Tissue plasminogen activator-like protease
11/09/2004	US6815463 For therapy of disease of cellular hyperproliferation in a subject
11/09/2004	US6815460 Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors
11/09/2004	US6815458 Nervous system disorders
11/09/2004	US6815457 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidin e-2,4-dione, maleic acid salt in polymorphic form
11/09/2004	US6815456 Antiserotonine agents; central nervous system disorders
11/09/2004	US6815455 Benzimidazole compounds and drugs containing the same
11/09/2004	US6815451 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
11/09/2004	US6815438 Heteroaryl-diazabicycloalkanes
11/09/2004	US6815436 Hyperglycemic agents; antidiabetic agents
11/09/2004	US6815433 Composition and method for the treatment of dysglucaemia
11/09/2004	US6815428 Pyrazole derivatives and diabetic medicine containing them
11/09/2004	US6814987 Compositions and methods of use for extracts of magnoliaceae plants
11/09/2004	US6814986 Composition for treating obesity and esthetic treatment process
11/09/2004	CA2274596C Compositions and methods for enhancing intestinal function
11/04/2004	WO2004095023A1 Novel method of screening
11/04/2004	WO2004094448A1 METHYLATED CpG POLYNUCLEOTIDE
11/04/2004	WO2004094429A1 Cannabinoid receptor ligands and uses thereof
11/04/2004	WO2004094424A1 Nitrogen-containing heterocyclic compounds and use thereof
11/04/2004	WO2004094421A1 Cannabinoid receptor ligands and uses thereof
11/04/2004	WO2004094417A1 Cannabinoid receptor ligands and uses thereof
11/04/2004	WO2004094404A1 4-imidazolin-2-one compounds
11/04/2004	WO2004094402A1 NOVEL SUBSTANCE HAVING α-GLUCOSIDASE INHIBITING ACTIVITY AND FOOD CONTAINING THE SAME
11/04/2004	WO2004094394A1 Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
11/04/2004	WO2004094362A1 CaSR ANTAGONIST
11/04/2004	WO2004093897A1 Compositions for mucosal and oral administration comprising hcg fragments
11/04/2004	WO2004093879A1 (3-{3-‘(2,4-bis-trifluormethyl-benzyl)-(5-ethyl-pyrimidin-2-yl)-amino!-propoxy}-phenyl)-acetic acid and related compounds as modulators of ppars and methods of treating metabolic disorders
11/04/2004	WO2004093877A1 Vitamin comprising pyroloquinoline quinone and use thereof
11/04/2004	WO2004093872A1 3-oxo-1, 3-dihydro-indazole-2-carboxylic acid amide derivatives as phospholipase inhibitors
11/04/2004	WO2004093823A2 Polyethelene glycol link glp-1 compounds
11/04/2004	WO2004069194A3 Use of the oxidoreductase ncb50r for diagnosings and treating diabetes
11/04/2004	WO2004067506A3 Substituted heterocyclic compounds
11/04/2004	WO2003087044A3 Novel carboxamide compounds for use in mch receptor related disorders
11/04/2004	WO2003086324A3 Preparation and use of a stable formulation of allosteric effector compounds
11/04/2004	WO2003077847A3 Substituted amides
11/04/2004	US20040220260 efficacious in producing nitric oxide in the skin, the mucous membranes or the scalp; treatment of psoriasis lesions and/or chronic ulcers; i.e. Ascorbyl 2-O-cinnamate
11/04/2004	US20040220254 Process for preparing 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl) ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
11/04/2004	US20040220230 transfroming growth factor antagonist; therapy for urogenital disorders, cardiovascular disorders
11/04/2004	US20040220225 Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications
11/04/2004	US20040220204 mixture of fatty ester, alkylene carbonate, butylene glycol, diethylene glycol, monoalkyl ether and thickeners
11/04/2004	US20040220200 Compositions useful as protein kinase inhibitors
11/04/2004	US20040220188 Alkylidene pyrazolidinedione derivatives
11/04/2004	US20040220186 phosphodiesterase inhibitors
11/04/2004	US20040220171 anticoagulants; immunomoderators; antiinflammatory agents
11/04/2004	US20040220159 osteoporosis, periodontal diseases, aging resistance, antilipemic agents, anticholesterol agents, canticancer agents, antiarthritic agents, sexual disorders
11/04/2004	US20040220148 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
11/04/2004	US20040220143 Oral delivery of macromolecules
11/04/2004	US20040220116 mixture with polysorbate; beverages, cosmetics, nutrient adjuvants, cleaning compounds,
11/04/2004	US20040220096 Method and compositions for treating dopaminergic and gabanergic disorders
11/04/2004	US20040220092 G-protein coupled receptors
11/04/2004	US20040219262 Food and vitamin preparations containing the natural isomer of reduced folates
11/04/2004	US20040219212 Single-daily dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle
11/04/2004	US20040219202 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety
11/04/2004	US20040219189 administering excitatory amino acid agonists to poultry; feeds
11/04/2004	US20040219148 comprising an agent that targets an interleukin-15 receptor and a second agent that inhibits a costimulatory signal transmitted between a T cell and an antigen-presenting cell; treating autoimmune diseases, AIDS, vascular injuries or organ, tissue or cell transplant recipients
11/04/2004	US20040219141 Reducer of blood glucose level increase reducer of body fat accumulation and food material
11/04/2004	DE29825080U1 Pharmazeutische Fenofibratzusammensetzung mit erhöhter Bioverfügbarkeit Pharmaceutical fenofibrate with increased bioavailability
11/04/2004	DE10314610A1 Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung New diphenylazetidinone with improved physiological properties, process for its preparation, pharmaceutical compositions containing them and their use
11/04/2004	CA2523364A1 Cannabinoid receptor ligands and uses thereof
11/04/2004	CA2523205A1 Cannabinoid receptor ligands and uses thereof
11/04/2004	CA2522793A1 Novel substance having .alpha.-glucosidase inhibiting activity and food containing the same
11/04/2004	CA2522560A1 Antisense modulation of apolipoprotein c-iii expression
11/04/2004	CA2521538A1 Cannabinoid receptor ligands and uses thereof
11/04/2004	CA2520908A1 Aryl compounds as modulators of ppars and methods of treating metabolic disorders
11/04/2004	CA2520655A1 Compositions for mucosal and oral administration comprising hcg fragments
11/04/2004	CA2518336A1 Polyethelene glycol link glp-1 compounds
11/03/2004	EP1473305A1 Novel glutamate receptor and utilization thereof
11/03/2004	EP1473303A1 Novel proteins and dnas thereof
11/03/2004	EP1473047A1 Microbial cellulose wound dressing, containing PHMB, for treating chronic wounds
11/03/2004	EP1473040A1 Use of human parathyroid hormone
11/03/2004	EP1473033A1 Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid
11/03/2004	EP1472515A2 MINRs AS MODIFIERS FO INSULIN RECEPTOR SIGNALING AND METHODS OF USE
11/03/2004	EP1472351A2 Amino acid sequences capable of facilitating penetration across a biological barrier
11/03/2004	EP1472341A2 Compositions and methods for restoring immune responsiveness in patients with immunological defects
11/03/2004	EP1472273A2 Compositions and methods for the treatement of immune related diseases
11/03/2004	EP1472270A1 Fractionation of phytosterol esters in oil
11/03/2004	EP1472269A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/03/2004	EP1472267A2 Rna interference mediated inhibition of protein tyrosine phosphatase type iva (prl3) gene expression using short interfering nucleic acid (sina)
11/03/2004	EP1472257A1 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
11/03/2004	EP1472255A1 Aza-arylpiperazines
11/03/2004	EP1472253A1 Sulphonyl compounds with 5 -ht6 receptor affinity
11/03/2004	EP1472245A2 Heteroaryl compounds useful as inhibitors of gsk-3
11/03/2004	EP1472244A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
11/03/2004	EP1472243A1 Piperidine derivatives and their use as antagonists of tachykinins
11/03/2004	EP1472241A1 Cytoprotective benzofuran derivatives
11/03/2004	EP1472237A1 Catechol bioisosteres
11/03/2004	EP1472228A1 Process for the manufacture of hmg-coa reductase inhibitors
11/03/2004	EP1472226A1 Heterocyclic amide compounds as apolipoprotein b inhibitors
11/03/2004	EP1472224A2 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
11/03/2004	EP1472220A1 Crystalline (r-(r,r))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-heptanoic acid calcium salt (2:1)
11/03/2004	EP1472215A2 (oxime)carbamoyl fatty acid amide hydrolase inhibitors
11/03/2004	EP1472214A2 Compounds for inhibiting insulin secretion and methods related thereto

1 ... 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 ... 1298